The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose tumors had mutations in the MAPK cell-signaling pathway, according to data from a phase I clinical trial published in Cancer Discovery, a journal of the American Association for Cancer Research.
First-in-class ERK1/2 inhibitor safe, shows early efficacy in patients with advanced solid tumors
↧
↧
Trending Articles
More Pages to Explore .....